Welcome, Guest. Please login or register.
March 26, 2019, 12:16:51 pm

Login with username, password and session length

  • Total Posts: 53834
  • Total Topics: 4504
  • Online Today: 320
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 87
Total: 87


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Epclusa Is Highly Effective at Treating Genotype 3 of Hepatitis C  (Read 916 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 575
    • Hep Mag
Twelve weeks of Gilead Sciences’ Epclusa (sofosbuvir/velpatasvir) boasts a high success rate in treating those with genotype 3 of hepatitis C virus (HCV), even when people have viral mutations associated with drug resistance.

Publishing their findings in Alimentary Pharmacology & Therapeutics, researchers conducted a multicenter cohort study of 293 people with genotype 3 of HCV who received medical care at 10 treatment centers across Germany. The participants were enrolled in the study between July 2016 and August 2017.

For more...


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.